Device type · JJY
Multi-Analyte Controls, All Kinds (Assayed)
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
JJY
Clinical Chemistry
Device class
Class I
FDA decisions since 2015
8
510(k), De Novo and PMA
Adverse event reports
1
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Multi-Analyte Controls, All Kinds (Assayed)
- Product code
- JJY
- Device class
- Class I
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.1660
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for JJY
Latest FDA decisions
- Multichem IA Plus510(k)
K162530 · Decided Mar 31, 2017 · 203 days after receipt
Device type: Multi-Analyte Controls, All Kinds (Assayed) (JJY) · Laboratory Medicine & Pathology
K163629 · Decided Mar 10, 2017 · 78 days after receipt
Device type: Multi-Analyte Controls, All Kinds (Assayed) (JJY) · Laboratory Medicine & Pathology
K163015 · Decided Jan 10, 2017 · 74 days after receipt
Device type: Multi-Analyte Controls, All Kinds (Assayed) (JJY) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
Reports received
1
Received Nov 1, 2025 to Nov 19, 2026. Includes 1 of another or unstated type.
Malfunction reports
0
0.0% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 1 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 10 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 3 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 1 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions1
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0159-2027 · Started Aug 17, 2026 · Posted by FDA Oct 15, 2026
Reason given: Vial-to-vial variability in MAS Omni"IMMUNE PRO Liquid Assayed Integrated Immunoassay Control, Level 1, Lot OPRO29061A results in low Parathyroid Hormone (PTH) recovery, which may lead to a delay in reporting patient PTH results.
Cause as FDA categorized it: Process change control
- OC-Auto FOBT-CHEK Negative Controls is the negative hemoglobin control materials designed to monitor FOBT (Fecal Occult Blood Test)Open, Classified
POLYMEDCO, INC. / POLYMEDCO CANCER DIAGNOSTIC PRODUCTS, LLC
Z-0538-2026 · Started Oct 6, 2025 · Posted by FDA Nov 17, 2025
Reason given: A labeling error was identified on the affected product. The expiration date on the kit box label and on the vial labels incorrectly stated the expiration date as 2026-01-16. The correct expiration date should be 2027-01-17.
Cause as FDA categorized it: Process control
Z-0415-2026 · Started Oct 1, 2025 · Posted by FDA Oct 30, 2025
Reason given: The firm received complaints from customers reporting vial-to-vial variability when using the control with high sensitivity Troponin I assays. This defect may lead to as delay in patient results for hs Troponin I assays.
Cause as FDA categorized it: Nonconforming Material/Component
89 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.